Drug Safety

Latest Headlines

Latest Headlines

Advera: AbbVie's Viekira Pak riskier than Gilead's Harvoni for hep C

AbbVie is facing bad news for its hep C powerhouse Viekira Pak as it dukes it out for dominance with Gilead Sciences in the hep C market. Healthcare informatics firm Advera Health Analytics looked at new side effect post-marketing safety reports on hep C treatments, including those for Gilead's Sovaldi and Harvoni and AbbVie's Viekira Pak, and found that AbbVie's drug was the riskiest option among the three meds.

Takeda keeps Actos settlement ball rolling with new resolutions

Takeda is settling the score with two plaintiffs over allegedly hiding cancer risks linked to its diabetes drug Actos, almost a month after the company announced that it would complete a settlement program that would resolve most of its pending litigation for similar claims over the med.

Advera Health Analytics: Novartis, Allergan Alzheimer's meds linked to abnormal behavior, blood pressure side effects

Healthcare informatics company Advera Health Analytics delved into FDA postmarketing safety reports and compiled data on Alzheimer's drugs. The firm found that Novartis' Exelon patch, Allergan's Namenda and Eisai's Aricept showed more reports of serious side effects than other drugs, with safety issues ranging from convulsions and gastrointestinal hemorrhage to respiratory failure and sudden death.

Backlash rages on over Purdue's pediatric OxyContin approval

Back in August, the FDA approved Purdue's powerful painkiller, OxyContin, for children ages 11 to 16. But nearly two months later, the public backlash hasn't died down.

How can Pradaxa, Xarelto and Eliquis finally unseat warfarin? Safety data, analyst says

New oral anticoagulants--such as Johnson & Johnson's Xarelto and Boehringer Ingelheim's Pradaxa--have been in fierce competition with one another for awhile now. But they still have a ways to go to displace the old-guard therapy warfarin--and one GlobalData analyst thinks she knows why.

New Hampshire AG launches investigation into opioid marketing

Amid growing backlash from state and local lawmakers over opioid marketing, New Hampshire is cracking down on several companies marketing the drugs, claiming that the drugmakers intentionally exaggerated their products' benefits while downplaying serious risks.

BioClinica buys pharmacovigilance outfit to continue evolution

BioClinica is continuing the rapid evolution that began 18 months ago when its new owners merged it with CCBR-SYNARC. The latest step in the process is the buyout of Synowledge, a provider of pharmacovigilance and regulatory affairs services and accompanying IT support.

3M recalls iodine applicators over possible toxic chemical contamination

Iodine is routinely used on patients ahead of operations to help protect against bacteria contamination. But what if the iodine itself is contaminated with a toxic chemical? That is the issue facing 3M, which is recalling thousands of cases of surgical applicators.

Sun Pharma recalls more than 216,000 bottles after label leaches chemical

Two years ago, Sun Pharma was before the U.S. Supreme Court defending a label for one of its generic drugs against claims that it didn't adequately warn against risks. Now the labels on some of its drugs are creating another kind of problem, leading to a recall of more than 216,000 bottles of drugs.

J&J faces Tylenol lobbying allegations in first case to go to trial over med

New court documents in the first trial over claims that Johnson & Johnson promoted its blockbuster painkiller, Tylenol, without disclosing potentially dangerous side effects show that J&J's McNeil Consumer Healthcare unit planned to lobby government officials to prevent the FDA from implementing safety restrictions, ProPublica reports.